Gemfibrozil for Nicotine Dependence
| Status: | Completed |
|---|---|
| Conditions: | Tobacco Consumers |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 11/30/-0001 |
| Start Date: | August 2013 |
| End Date: | August 2015 |
Testing the PPAR Hypothesis of Nicotine Dependence in Humans: Gemfibrozil as a Novel Treatment for Tobacco Addiction
Gemfibrozil will result in diminished nicotine reinforcement, an attenuated response to
smoking cues, and an increase in smoking abstinence compared with placebo. The laboratory
measures will prove valid in predicting abstinence. The difference in laboratory measures,
when comparing gemfibrozil and placebo conditions, will predict the difference in abstinence
days, when comparing the gemfibrozil and placebo conditions.
Inclusion Criteria:
- 18-65 year old males and females
- smoking at least 10 cigarettes per day for at least 2 years
- intend to quit smoking within the next 3 months
- medically and psychologically healthy as determined by screening criteria
- women capable of becoming pregnant must agree to use contraceptives during the study
Exclusion Criteria:
- currently attempting to quit smoking
- treatment for tobacco addiction in the past 3 months
- use of nicotine replacement products, bupropion, or varenicline in the past 3 months
as an aid to quit or reduce smoking
- use of any oral tobacco product in the past 3 months
- history of drug or alcohol dependence within last 5 years
- consumption of more than 15 alcoholic drinks per week on average during the past
month
- use of any illicit drug more than once per week on average during the past month
- current use of gemfibrozil or other fibrate medication
We found this trial at
1
site
6001 Executive Boulevard, Room 5213
Baltimore, Maryland 20892
Baltimore, Maryland 20892
301-443-1124
National Institute on Drug Abuse NIDA's mission is to lead the Nation in bringing the...
Click here to add this to my saved trials
